Assuming the company does owe Hepalink $8M by June of 2022, this would then be on top of the $US6M convertible debentures issued in May 2021, unless of course Hepalink chooses to convert or things get kicked down the road again.

So, where does Resverlogix get that kind of money?  The only thing I can see is that they are counting on a successful Covid trial that then ultimately leads to the commercialization of ABL by Eversana.  If the Covid trial doesn't pan out then Tada is right in that it will be very difficult for the company going forward.  However, there is too much at stake now for a BoM2 trial to not go ahead and I would be surprised if contingency plans for that have not already been at least discussed.  

Nevertheless, the Covid trial comes first and, in spite of my earlier skepticism that this would or could be a commercial game changer for the company, I hope to be proved wrong.  How quickly this might happen if the trial proves successful is clearly open for debate, but it would definitely get media attention if it is successful.  Fingers crossed.